|Budget Amount *help
¥2,100,000 (Direct Cost : ¥2,100,000)
Fiscal Year 1993 : ¥500,000 (Direct Cost : ¥500,000)
Fiscal Year 1992 : ¥1,600,000 (Direct Cost : ¥1,600,000)
Endothelial cell injury may play a role in major complications after bone marrow transplantation. To assess this, a novel marker of endothelial in jury, serum thrombomodulin was measured in 21 day 100, using an enzyme immunoassay (Ishii et al : Thrombosis and Haemostasis 63 : 157-162,1990). The maximal levell of serum thrombomodulin was markedly elevated in sixteen patients with major trasplant related complications, including 7 with graft versus host disease, 4 with veno-occlusive disease, 2 with interstitial pneumonitis and 3 with hemorrhagic cystitis (48.4 (〕SY.+-.〔) 17.4ng/ml) as compared with the 31 normal subjects (20 (〕SY.+-.〔) 2.9ng/ml, P<0.01). In contrast, the serum levels of thrombomodulin were normal in 5 patients without major complications (21.7 (〕SY.+-.〔) 3.5ng/ml, N.S.). Serum levels of thrombomodulin were closely associated with the clinical changes of major complications. We also measured tumor necrosis factor alpha (TNF alpha ) in sone patients with major complications and found the serum levels of TNF alpha correlated with serum thrombomodulin in these patients. These results suggest that the serum level of thromvomodulin may be a useful marker of endothelial cell injury to predict the major transplant related complications. Further studies are needed to prove the phthophysiological role of thrombomodulin in complications after bone marrow transplantation.